Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor.

ABSTRACT:

Background

Tenosynovial giant-cell tumor (TGCT) is a rare condition characterized by pain, stiffness, and limited range of motion. Pexidartinib is the first regulatory-approved systemic therapy for adult patients with symptomatic TGCT not amenable for surgery. This study evaluated symptom improvement in patients who newly initiated pexidartinib.

Methods

A longitudinal, observational study collected data on patient-reported outcomes, demographics, disease history, pexidartinib dosing, and clinicians' perspective.

Results

Identified from the TURALIO Risk Evaluation and Mitigation Strategy (REMS) program, 80 patients who newly initiated pexidartinib between April and October 2022 received a study invitation, and 14 completed the baseline assessment; mean (SD) age was 39.

SUBMITTER: Dai D 

PROVIDER: S-EPMC12330255 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature